Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma;Syndrome myasthénique de Lambert-Eaton associé à un carcinome épidermoïde de la corde vocale

Revue Neurologique

Volumn 164, Issue 1, 2008, Pages 72-76

  Shipley, E ^a   Krim, E ^b   Deminiere C ^c   Lagueny, A ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL DU BOCAGE   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

Anti voltage gated calcium channel antibody; Lambert Eaton myasthenic syndrome; Paraneoplastic syndrome; Potentiation; Vocal cord cancer

Indexed keywords

3,4 DIAMINOPYRIDINE; HUMAN IMMUNOGLOBULIN; PYRIDOSTIGMINE; 3,4-DIAMINOPYRIDINE; 4 AMINOPYRIDINE; CHOLINESTERASE INHIBITOR; DRUG DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; ELECTROPHYSIOLOGY; HUMAN; LARYNX CARCINOMA; MALE; NERVE STIMULATION; ENDOSCOPY; EXERCISE; LARYNX DISORDER; LARYNX TUMOR; MIDDLE AGED; MUSCLE DISEASE; NERVE CONDUCTION; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; ULNAR NERVE; VOCAL CORD;

4-AMINOPYRIDINE; CARCINOMA, SQUAMOUS CELL; CHOLINESTERASE INHIBITORS; ELECTROPHYSIOLOGY; ENDOSCOPY; EXERCISE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MUSCULAR DISEASES; NEURAL CONDUCTION; POTASSIUM CHANNEL BLOCKERS; PYRIDOSTIGMINE BROMIDE; ULNAR NERVE; VOCAL CORDS; VOICE DISORDERS;

EID: 42449141910     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2007.08.004     Document Type: Article

References (14)

1. AAEM Quality Assurance Commitee. American Association Of Electrodiagnostic Medicine. (2001). Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve, 24, 1239-1247.
2. Bady B., Vial C., and Chauplannaz G. Syndrome de Lambert-Eaton : étude clinique et électrophysiologique de 18 cas associés à un cancer du poumon. Rev. Neurol. 148 (1992) 513-519
3. Dropcho E.J. Neurologic paraneoplastic syndromes. J. Neurol. Sci. 153 (1998) 264-278
4. Ferlito A., and Rinaldo A. Paraneoplastic syndromes in patients with laryngeal and hypopharyngeal cancers. Ann. Otol. Rhinol. Laryngol. 109 (2000) 109-117
5. Fournier E. (2000). Examen électromyographique et étude de la conduction nerveuse. Collection Explorations Fonctionnelles Humaines. Éditions Médicales Internationales.
6. Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., and Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 (2002) 764-766
7. Greenberg D.A. Neuromuscular disease and calcium channels. Muscle Nerve 22 (1999) 1341-1349
8. Maddison P., Lang B., Mills K., and Newsom-Davis J. Long term outcome in Lambert-Eaton myathenic syndrome without lung cancer. J. Neurol. Neurosurg. Psychiatry 70 (2001) 212-217
9. Martin-Moutot N., de Haro L., and Seagar M. Dosage et spécificité d'autoanticorps anti-canaux calcium dans le syndrome myasthenique de Lambert-Eaton. Rev. Neurol. 160 (2004) S28-S34
10. Nakao Y.K., Motomura M., Fukudome T., et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59 (2002) 1773-1775
11. Oh S.J., Kurokawa K., Claussen G.C., and Ryan H.F. Electrophysiological diagnostic criteria of Lambert-Eaton myathenic syndrome. Muscle Nerve 32 (2005) 515-520
12. Oh S.J., Hatanaka Y., Claussen G.C., and Sher E. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 35 (2007) 178-183
13. O'Neill J.H., Murray M.F., and Newsom-Davis J. The Lambert-Eaton myathenic syndrome. Brain 111 (1988) 577-596
14. Sharshar T., Chevret S., Mazighi M., et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J. Neurol. 247 (2000) 286-290